Skip to main content
TipRanks
Go Ultimate75% OFF

Oramed Pharm (ORMP) Stock Price & Analysis

533 Followers

ORMP Stock Chart & Stats

$3.90$0.19(5.12%)
At close: 4:00 PM EST
$4$4.5$5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$3.70 - $4.05
52-Week Range
$2.25 - $5.47
Previous Close
$3.71
Volume
N/A
Average Volume (3M)
129.36K
Market Cap
$161.33M
Enterprise Value
$154.55M
Total Cash (Recent Filing)
$29.52M
Total Debt (Recent Filing)
$1.53M
Price to Earnings (P/E)
1.1
Beta
0.48
Next Earnings
Jul 14, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Strong Capitalization

Very low debt relative to equity gives Oramed meaningful financial flexibility and reduces near-term solvency pressure. This capitalization can help fund clinical development and absorb operating losses, although its lasting value depends on converting resources into sustainable business performance.

Oral Peptide Delivery Focus

A platform focused on converting traditionally injectable peptide medicines into oral treatments addresses a meaningful usability barrier in drug delivery. If clinical development succeeds, this approach could support differentiated products and broaden the company’s strategic partnering or commercialization opportunities.

Governance Continuity

Re-election of the incumbent board and auditor approval preserve governance continuity during ongoing clinical-stage development. Stable oversight can support consistent capital allocation, regulatory execution, and long-term program decisions, though the votes do not themselves establish commercial or clinical success.

Bears Say

Minimal Commercial Revenue

The absence of a meaningful recurring revenue base shows that Oramed has not yet established a durable commercial engine. This leaves future funding capacity dependent on existing resources, financing, partnerships, or successful product development rather than internally generated operating revenue.

Persistent Operating Losses

Recurring operating losses indicate that the current business model is not covering its ongoing development and corporate costs. Until revenue or product economics improve, continued losses can consume capital, limit strategic flexibility, and make eventual profitability dependent on uncertain clinical and commercialization outcomes.

Negative Cash Generation

Negative operating and free cash flow means reported earnings are not currently translating into cash that can fund the business. Persistent burn increases reliance on the balance sheet over time and may require additional financing or other capital sources if development spending continues.

Oramed Pharm News

ORMP FAQ

What was Oramed Pharm’s price range in the past 12 months?
Oramed Pharm lowest stock price was $2.25 and its highest was $5.47 in the past 12 months.
What is Oramed Pharm’s market cap?
Oramed Pharm’s market cap is $161.33M.
When is Oramed Pharm’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oramed Pharm’s earnings last quarter?
Oramed Pharm released its earnings results on Jul 15, 2026. The company reported $2.76 earnings per share for the quarter, beating the consensus estimate of $0.43 by $2.33.
Is Oramed Pharm overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Oramed Pharm pay dividends?
Oramed Pharm pays a dividend of $0.25 which represents an annual dividend yield of ―. See more information on Oramed Pharm dividends here
What is Oramed Pharm’s EPS estimate?
Oramed Pharm’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharm have?
Oramed Pharm has 43,485,943 shares outstanding.
What happened to Oramed Pharm’s price movement after its last earnings report?
Oramed Pharm reported an EPS of $2.76 in its last earnings report, beating expectations of $0.43. Following the earnings report the stock price went up 1.5%.
Which hedge fund is a major shareholder of Oramed Pharm?
Hedge funds hold Oramed Pharm shares: the largest hedge-fund position in Oramed Pharm is 72,325,995 shares, and hedge funds increased their holdings by 1.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology